Related references
Note: Only part of the references are listed.Cancer immune therapy for lymphoid malignancies: recent advances
Uffe Klausen et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
Cancer vaccines on the move
Jacques Banchereau et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers
Vinay Prasad
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
Bispecific antibody based therapeutics: Strengths and challenges
Archana Thakur et al.
BLOOD REVIEWS (2018)
Randomised phase II trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
Maren Knoedler et al.
BRITISH JOURNAL OF CANCER (2018)
Prognostic Effect of CD20 Expression in Adult B-cell Acute Lymphoblastic Leukemia
Reiban-Espinoza Esteban et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies
Gregory Z. Ferl et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas
Marcus P. Watkins et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma.
Joshua Ryan Richter et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers.
Martin Wermke et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer
Paul A. Moore et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia
E. Dianne Pulte et al.
ONCOLOGIST (2018)
APVO210: A Bispecific Anti-CD86-IL-10 Fusion Protein (ADAPTIR™) to Induce Antigen-Specific T Regulatory Type 1 Cells
Laurence Pellerin et al.
FRONTIERS IN IMMUNOLOGY (2018)
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE (R)) antibody construct, in patients with refractory solid tumors
Maxim Kebenko et al.
ONCOIMMUNOLOGY (2018)
APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR® molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine release
Michael R. Comeau et al.
CANCER RESEARCH (2018)
The therapeutic potential of AMV564, a novel bispecific bivalent (2x2) T-cell engager, for the treatment of CD33-expressing hematologic malignancies
Tae H. Han et al.
CANCER RESEARCH (2018)
A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.
Sadhna Shankar et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase 1 dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors.
Yoshitaka Ogita et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice
Timothy S. Fisher et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data
Arie Barlev et al.
ADVANCES IN THERAPY (2017)
52TiPA phase 1 study of GBR 1302 in subjects with HER2-positive cancers
M. Wermke et al.
ANNALS OF ONCOLOGY (2017)
MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
Liqin Liu et al.
CLINICAL CANCER RESEARCH (2017)
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
S. Hipp et al.
LEUKEMIA (2017)
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
Giovanni Martinelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Recent advances of bispecific antibodies in solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies
David J. Byun et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors
Takahiro Ishiguro et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Highly Specific and Effective Targeting of EG FRvIII-Positive Tumors with TandAb Antibodies
Kristina Ellwanger et al.
FRONTIERS IN ONCOLOGY (2017)
Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer.
W. M. Fiedler et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase I study of the bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers.
Martin Wermke et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma.
Takami Sato et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Anti-SSTR2 x anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors
Sung-Hyung Lee et al.
CANCER RESEARCH (2017)
Developments in therapy with monoclonal antibodies and related proteins
H. Michael Shepard et al.
CLINICAL MEDICINE (2017)
Phase Ia and lb studies of the novel carcinoembryonic antigen (CEA) 1-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment
T. Yuraszeck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
Muneera Al-Hussaini et al.
BLOOD (2016)
Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature
David Kavanagh et al.
BLOOD (2016)
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
A. Viardot et al.
BLOOD (2016)
A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors
N. Haense et al.
BMC CANCER (2016)
anti-ROR1 x anti-CD3 ADAPTIRTm molecule, ES425, redirects T-cell cytotoxicity and inhibits tumor growth in preclinical models of triple negative breast cancer
John W. Blankenship et al.
CANCER RESEARCH (2016)
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2016)
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
Elodie Picarda et al.
CLINICAL CANCER RESEARCH (2016)
In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing
Steffi Lehmann et al.
CLINICAL CANCER RESEARCH (2016)
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas
Michael Pishvaian et al.
CLINICAL COLORECTAL CANCER (2016)
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Marco Ruella et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Gabriela Hernandez-Hoyos et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma
Mark R. Middleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
Lawrence G. Lum et al.
CLINICAL CANCER RESEARCH (2015)
Bispecific antibodies and their applications
Gaowei Fan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells
Uwe Reusch et al.
MABS (2015)
ImmTACs for targeted cancer therapy: Why, what, how, and which
Joanne Oates et al.
MOLECULAR IMMUNOLOGY (2015)
Alternative molecular formats and therapeutic applications for bispecific antibodies
Christoph Spiess et al.
MOLECULAR IMMUNOLOGY (2015)
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies
Liping L. Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Gurunadh R. Chichili et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
Eric J. Smith et al.
SCIENTIFIC REPORTS (2015)
Exploring the Rising Incidence of Neuroendocrine Tumors: A Population-Based Analysis of Epidemiology, Metastatic Presentation, and Outcomes
Julie Hallet et al.
CANCER (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma.
Elisabeth De Vries et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells
Giovanna Bossi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Current advances in T-cell-based cancer immunotherapy
Mingjun Wang et al.
IMMUNOTHERAPY (2014)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
Michael D. Oberst et al.
MABS (2014)
ALPPS for Patients with Colorectal Liver Metastases: Effective Liver Hypertrophy, but Early Tumor Recurrence
Karl J. Oldhafer et al.
WORLD JOURNAL OF SURGERY (2014)
T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy
Ignacio Melero et al.
CANCER DISCOVERY (2014)
Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies
Ian M. Zitron et al.
BMC CANCER (2013)
Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial
Raymund Buhmann et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct
M. Aigner et al.
LEUKEMIA (2013)
Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity
Whitney Shatz et al.
MABS (2013)
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Aran F. Labrijn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger et al.
BLOOD (2012)
IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma
Namir J. Hassan et al.
CANCER RESEARCH (2012)
RECRUIT-TandAbs®: harnessing the immune system to kill cancer cells
Fionnuala McAleese et al.
FUTURE ONCOLOGY (2012)
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
Matthias Friedrich et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets
Maxim Yankelevich et al.
PEDIATRIC BLOOD & CANCER (2012)
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
Paul A. Moore et al.
BLOOD (2011)
Species-Specific Determinants in the IgG CH3 Domain Enable Fab-Arm Exchange by Affecting the Noncovalent CH3-CH3 Interaction Strength
Aran F. Labrijn et al.
JOURNAL OF IMMUNOLOGY (2011)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy
Diane Seimetz et al.
CANCER TREATMENT REVIEWS (2010)
Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
Syd Johnson et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Structural and functional characterization of the trifunctional antibody catumaxomab
Dirk Chelius et al.
MABS (2010)
Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
Ines Herrmann et al.
PLOS ONE (2010)
Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels
Michael Stanglmaier et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Expression of the target receptor CD33 in CD34(+)/CD38(-)/CD123(+) AML stem cells
A. W. Hauswirth et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2007)
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer
Philipp Kiewe et al.
CLINICAL CANCER RESEARCH (2006)
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
A Ghosh et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors
M Sen et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2001)
Share Paper
